CSL gets European OK for Novartis flu vaccines purchase; GSK's malaria vax may pick up key approval Friday;

> CSL received regulatory approval from the European Commission on its deal to buy Novartis' ($NVS) flu vaccine business, though the deal has not closed yet. Report

> European regulators could recommend GlaxoSmithKline's ($GSK) malaria vaccine--the world's first such shot--on Friday, Reuters reported. Story

> Focusing on blocking the disease's transmission process, a professor from Oklahoma University is working to develop a malaria vaccine. Report

And Finally... Portland State University virologists discovered how to neutralize viruses by coating them in silica and then bring them back to life by removing the coat--the team dubbed them "zombie viruses." Report

Suggested Articles

Daiichi Sankyo says it still unable to fulfill a government mandate to be able to produce enough H5N1 flu vaccine to fight an epidemic in Japan.

GSK’s Shingrix has continuously impressed industry watchers with its growth, and the company just added another large market to its list: China.

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.